Provider education and point-of-care antibody testing benefit HCV patients

A series of interventions improved testing, linkage to care and treatment initiation in patients with hepatitis C, according to a study published in The Lancet Gastroenterology and Hepatology.

Dr. Evan B. Cunningham

“The advent of direct-acting antiviral therapy (DAA) for the treatment of HCV has been one of the greatest clinical advances in decades, allowing for optimism that HCV could be eliminated globally.” Evan B. Cunningham, Doctor, associate professor in the viral hepatitis clinical research program at the Kirby Institute in Australia, he told Healio. “Since DAAs have become commonplace, considerable research has been done to optimize HCV models of care; however, there was no systematic review to bring everything together. This review sought to highlight those interventions that could be most effective in advancing the drive towards HCV elimination.”